Lord, Abbett & Co. LLC Legend Biotech Corp Transaction History

Lord, Abbett & Co. LLC

  • $31.4 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Oct 07, 2024
SELL
$57.25 - $69.74 $3.29 Million - $4.01 Million
-57,526 Reduced 94.44%
3,385 $204,000
Q4 2023

Feb 12, 2024
SELL
$57.25 - $69.74 $3.29 Million - $4.01 Million
-57,526 Reduced 94.44%
3,385 $204,000
Q3 2023

Oct 07, 2024
SELL
$63.16 - $76.5 $31.8 Million - $38.5 Million
-502,798 Reduced 89.19%
60,911 $4.09 Million
Q3 2023

Nov 13, 2023
SELL
$63.16 - $76.5 $31.8 Million - $38.5 Million
-502,798 Reduced 89.19%
60,911 $4.09 Million
Q2 2023

Oct 07, 2024
BUY
$46.28 - $75.01 $23.5 Million - $38.1 Million
507,281 Added 898.99%
563,709 $38.9 Million
Q2 2023

Aug 14, 2023
BUY
$46.28 - $75.01 $23.5 Million - $38.1 Million
507,281 Added 898.99%
563,709 $38.9 Million
Q1 2023

Oct 07, 2024
SELL
$43.42 - $57.37 $14.8 Million - $19.6 Million
-341,328 Reduced 85.81%
56,428 $2.72 Million
Q1 2023

May 12, 2023
SELL
$43.42 - $57.37 $14.8 Million - $19.6 Million
-341,328 Reduced 85.81%
56,428 $2.72 Million
Q4 2022

Oct 07, 2024
BUY
$38.8 - $55.46 $15.4 Million - $22.1 Million
397,756 New
397,756 $19.9 Million
Q4 2022

Feb 10, 2023
BUY
$38.8 - $55.46 $448,605 - $641,228
11,562 Added 2.99%
397,756 $19.9 Million
Q3 2022

Nov 14, 2022
SELL
$38.15 - $57.1 $14.2 Million - $21.2 Million
-371,985 Reduced 49.06%
386,194 $15.8 Million
Q2 2022

Aug 12, 2022
BUY
$33.54 - $55.0 $25.4 Million - $41.7 Million
758,179 New
758,179 $41.7 Million

Others Institutions Holding LEGN

# of Institutions
225
Shares Held
74.3M
Call Options Held
279K
Put Options Held
350K
View Full List

About Legend Biotech Corp

LEGN Quotes by TradingView
  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email